IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapy
Year: 2024
Type: article
Abstract: PD-1/PD-L1 is an important signaling pathway in the adaptive immune system. The CD47/SIRPα signaling pathway is a crucial "do not eat me" signal for innate immunity. This study evaluated the anti-tumor mechanism of IMM2520 in vitro and in vivo . IMM2520 was generated using the "mab-trap" platform. IMM2520 showed high affinity to PD-L1 and relatively lower affinity to CD47, displaying preferential binding to PD-L1 on tumor cells. IMM2520 had the potent ability to inhibit the PD-1/PD-L1 and CD47/SIRPα signaling pathways and killed tumor cells through ADCC and ADCP. Importantly, IMM2520 did not bind to human red blood cells or induce erythrocyte agglutination. IMM2520 demonstrated a tendency to bind to CD47 + /PD-L1 + tumor cells, reducing its binding to CD47 single-positive cells. In mouse transplantation models, compared with the first-generation CD47/PD-L1 BsAb (IMM2505), IMM2520 exhibited stronger and dose-dependent antitumor activity. These findings imply that IMM2520 may offer a novel therapeutic alternative for cancer patients.
Source: Heliyon
Authors: Chunmei Yang, Song Li, Dianze Chen, Dandan Liu, Yanan Yang, Huiqin Guo, Nana Sun, Xing Bai, Guanghui Li, Ruliang Zhang, Tianxiang Wang, Li Zhang, Liang Peng, Sijin Liu, Wei Zhang, Gui Zhao, Xiaoping Tu, Wenzhi Tian
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,100
OpenAlex ID: W4403847937